Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced significant progress in its clinical development program, including positive six-month results from its first-in-human (FIH) study of the Ocumetics Lens, a dynamic intraocular lens designed to restore natural accommodation after cataract surgery. The encouraging data have enabled the company to advance to Group Two surgeries, now scheduled for the third quarter of 2026 in Mexico City.
The company has completed the design of a next-generation solid-state accommodating intraocular lens, which incorporates advancements in manufacturability, surgical performance, and scalability. Manufacturing of this redesigned lens has commenced with German partner Amiplant GmbH, in preparation for the upcoming Group Two procedures. The new lens features a simplified one-piece architecture with no internal fluids, aiming to improve consistency and long-term reliability.
Ocumetics has also met all regulatory requirements necessary to proceed with Group Two enrollment. The company is concurrently pursuing a financing initiative to fund the completion of the FIH study and accelerate commercialization activities. Proceeds are expected to support manufacturing, sterilization, packaging, regulatory programs, and strategic partnership initiatives.
Management has engaged in discussions with four of the world's seven largest ophthalmic companies, with several expressing interest in reviewing additional clinical data following Group Two surgeries. Follow-up meetings are tentatively scheduled for early Q4 2026, contingent upon one-month patient results from the next cohort.
Six-month follow-up data from Group One patients continue to demonstrate favorable safety and performance outcomes, with successful implantation and post-operative recovery. Notably, one patient previously considered legally blind has regained sufficient vision to qualify for driving. These outcomes have provided the foundation for advancing the clinical program.
The company expects that positive one-month results from Group Two patients will represent a meaningful value-creation milestone, supporting larger clinical studies, regulatory submissions, and eventual commercialization. With manufacturing underway and regulatory milestones achieved, Ocumetics believes it is well positioned to execute the next phase of its development strategy.
